Generic placeholder image

Current Nanomedicine


ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Mini-Review Article

Nanomedicine as a Better Therapeutic Approach: An Overview

In Press, (this is not the final "Version of Record"). Available online 19 January, 2024
Author(s): Arnab Das and Srijita Chakrabarti*
Published on: 19 January, 2024

DOI: 10.2174/0124681873283310231228125729

Price: $95


The fields of nanotechnology and nanomedicine have undergone a revolution. There has been a striking rise in authorized nanomedicines since 1980. Apart from functioning as therapeutic agents, they also act as carriers for delivering various active pharmaceuticals to target organs. The ultimate goal of nanomedicine has always been the generation of translational technologies that can improve current therapies. Nanocrystals, nanotubes, liposomes, exosomes, solid lipid nanoparticles, polymeric nanoparticles, and metallic and magnetic nanoparticles are examples of nanostructures that are now in the market as well as in ongoing research. The preparation of these nanomaterials requires consideration of a number of difficulties. Only a few of these nano-materials were successful in obtaining marketing permission after passing all required toxicological and ethical evaluations and making them affordable to users and, at the same time, profitable to investors. Cancer, Central nervous system (CNS) diseases, and Cardiovascular (CVS) diseases represented the primary targets of nanotechnology applied to medicine. Therefore, this review article is focused on providing a summary of several nano-based delivery systems, including their limitations and prospects in different therapeutic fields.

Keywords: Cancer, CNS Diseases, CVS Diseases, nanomedicine, pharmaceutical, targeted drug delivery.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy